CareLit · DOI-Nachweis · Pneumologie
T Safety And Performance In Respimat® (TIOSPIR™): Safety And Efficacy In Patients With T HH® Use At Baseline
DOI 10.1055/s-0036-1572049
Bibliografische Angaben
Nachweis in CareLit
Autor:innenR Koczulla, P Calverley, A Anzueto, R Dahl, A Müller, A Fowler, N Metzdorf, R Wise, D Dusser
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Rationale: The TIOSPIR™ trial showed that tiotropium (T) Respimat® (Resp) 5 µg and HandiHaler® (HH) 18 µg have similar safety and exacerbation (exa) efficacy profiles in patients (pts) with COPD. We present results for all pts using T HH® at baseline. Methods: TIOSPIR™ (n = 17,135) compared safety and efficacy of once-daily T Resp 5 and 2.5 µg with once-daily HH 18 µg in pts with COPD. Primary endpoints were time to…
Zitieren
Zitierempfehlung
R Koczulla, P Calverley, A Anzueto, R Dahl, A Müller, A Fowler, N Metzdorf, R Wise, D Dusser (2016) T Safety And Performance In Respimat® (TIOSPIR™): Safety And Efficacy In Patients With T HH® Use At Baseline. Pneumologie (02). https://doi.org/10.1055/s-0036-1572049
Mit CareLit weiterarbeiten